Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2012-2017

  De Jonge, Maja J A ^a   Verweij, Jaap ^a   Planting, André S T ^a   Van Der Burg, Maria E L ^a   Stoter, Gerrit ^a   De Boer Dennert, Maureen M ^a   De Bruijn, Peter ^a   Brouwer, Eric ^a   Vernillet, Laurent ^b   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DRUG METABOLITE; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA ADDUCT; DRUG CLEARANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ADULT; AGED; CAMPTOTHECIN; CISPLATIN; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 6544245174     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. De Jonge, M. J. A., Sparreboom, A., and Verweij, J. The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. Cancer Treat. Rev., 24: 205-220, 1998.
2. Ma, J., Maliepaard, M., Nooter, K., Boersma, A. W. M., Verweij, J., Stoter, G., and Schellens, J. H. M. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother. Pharmacol., 41: 307-316, 1998.
3. Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S., and Miura, Y. Effects of CPT-11 in combination with other anticancer agents in culture. Int. J. Cancer, 50: 604-610, 1992.
4. Keane, T. E., El-Galley, R. E., Sun, C., Petros, J., Dillahey, D., Gomaa, A., Graham, S. D., Jr., and McGuire, W. P. Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. J. Urol., 160: 252-256, 1998.
5. Rowinsky, E. K., Kaufmann, S. H., Baker, S. D., Grochow, L. B., Chen, T-L., Peereboom, D., Bowling, M. K., Sartorius, S. E., Ettinger, D. S., Forastiere, A. A., and Donehower, R. C. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol., 14: 3074-3084, 1996.
6. De Jonge, M. J. A., Sparreboom, A., Planting, A. S. T., De Boer-Dennert, M. M., Mantel, M. A., Van der Burg, M. E. L., Ross, G., Stoter, G., and Verweij, J. Sequence-dependent side effects of oral topotecan with intravenous cisplatin in a phase I and pharmacological study in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 17: 204a, 1998.
7. Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K., and Kishimoto, S. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol., 10: 1775-1780, 1992.
8. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K., Tamanoi, M., Nitta, T., Hirashima, T., Negoro, S., and Takada, M. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer, 68: 777-782, 1993.
9. Shirao, K., Shimada, Y., Kondo, H., Saito, D., Yamao, T., Ono, H., Yokoyama, T., Fukuda, H., Oka, M., Watanabe, Y., Ohtsu, A., Boku, N., Fujii, T., Oda, Y., Muro, K., and Yoshida, S. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J. Clin. Oncol., 15: 921-927, 1997.
10. Ueoka, H., Tabata, M., Kiura, K., Shibayama, T., Gemba, K., Segawa, Y., Chikamori, K., Yonei, T., Hiraki, S., and Harada, M. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br. J. Cancer, 79: 984-990, 1999.
11. Mori, K., Ohnishi, T., Yokoyama, K., and Tominaga, K. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 39: 327-332, 1997.
12. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, T., Negoro, S., Takifuji, N., and Takada, M. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J. Clin. Oncol., 12: 90-96, 1994.
13. Mori, K., Hirose, T., Machida, S., Yokoyama, K., and Tominaga, K. A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur. J. Cancer, 33: 503-505, 1997.
14. De Bruijn, P., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., and Sparreboom, A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr., 698: 277-285, 1997.
15. Sparreboom, A., De Bruijn, P., De Jonge, M. J. A., Loos, W. J., Stoter, G., Verweij, J., and Nooter, K. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J. Chromatogr., 712: 225-235, 1998.
16. Schellens, J. H. M., Ma, J., Planting, A. S. T., Van der Burg, M. E. L., Van Meerten, E., De Boer-Dennert, M., Schmitz, P. I. M., Stoter, G., and Verweij, J. Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors. Br. J. Cancer, 73: 1569-1575, 1996.
17. Sparreboom, A., De Jonge, M. J. A., De Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., Van Alphen, R. J., Mathijssen, A. H. J., Stoter, G., and Verweij, J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin. Cancer Res., 4: 2747-2754, 1998.
18. Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
19. Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., and Wienkers, L. C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos., 25: 1157-1164, 1997.
20. LeBlanc, G. A., Sundseth, S. S., Weber, G. F., and Waxman, D. J. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res., 52: 540-547, 1992.
21. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubjko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
22. Relling, M. V., McLeod, H. L., Bowman, L. C., and Santana, V. M. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther., 56: 503-511, 1994.